Evra

Short answer: for most people who need systemic estrogen, the transdermal route (patch or gel) is generally safer than oral estrogen—especially with regard to blood clots (venous thromboembolism) and some liver/metabolic effects. Why: Oral estrogens go through the liver first (“first‑pass”), which raises clotting factors, increasing VTE risk (and can raise triglycerides and affect CRP). Multiple studies and meta‑analyses show oral menopausal estrogen is associated with a higher VTE risk than transdermal. Transdermal estradiol (patch or gel) delivers hormone directly into the bloodstream, avoids the first‑pass hepatic effect, gives steadier blood levels, and is not associated with the same increase in VTE risk in observational studies. Oral estrogen may also increase gallbladder disease more than transdermal. Both routes carry other risks that depend on dose, whether a progestin is also used (required if you have a uterus), age, time since menopause, and personal risk factors (smoking, obesity, prior clots, thrombophilia, stroke, active cancer). Practical choices (brand examples): Transdermal patches: Climara, Vivelle‑Dot (Evra in some countries), Alora, Minivelle — commonly used for lower VTE risk and steady estradiol levels. Transdermal gels/solutions: EstroGel, Divigel — alternatives if you don’t like patches. Oral tablets: Estrace (micronized estradiol) or Premarin (conjugated equine estrogens) — used widely but have higher hepatic effects than transdermal. Other important points: If you have a history of VTE, known thrombophilia (e.g., factor V Leiden), recent stroke, or active liver disease, systemic estrogen may be contraindicated — and transdermal is usually preferred over oral only after specialist input. If you have a uterus, you’ll usually need a progestogen as well to prevent endometrial hyperplasia. Micronized progesterone (Prometrium) is often used and may have a different side‑effect profile than some synthetic progestins. Use the lowest effective dose for the shortest time needed and review periodically. Avoid unregulated “compounded bioidentical” products unless closely supervised (they’re not FDA‑standardized). Next step: discuss your personal medical history (age, smoking, clot history, cardiovascular risk, family history of thrombosis or breast cancer, whether you still have your uterus) with your clinician to choose route, dose, and whether you need progestogen. I can help you list questions to bring to your provider or summarize risks based on specific personal factors if you want.

Mentioned in position 3 of 10